|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Sage Therapeutics, Inc. (SAGE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
58,290,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,000 |
25,500 |
Total Buy Value |
$0 |
$0 |
$87,779 |
$839,364 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
2 |
4 |
Total Shares Sold |
0 |
0 |
0 |
11,643 |
Total Sell Value |
$0 |
$0 |
$0 |
$519,413 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Robichaud Albert |
Chief Scientific Officer |
|
2019-12-09 |
4 |
B |
$64.16 |
$1,604,000 |
D/D |
25,000 |
136,400 |
0.01 |
- |
|
Robichaud Albert |
Chief Scientific Officer |
|
2019-12-09 |
4 |
OE |
$1.36 |
$316,746 |
D/D |
15,743 |
111,400 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-09-11 |
4 |
OE |
$0.45 |
$2,070 |
D/D |
4,600 |
47,030 |
|
- |
|
Kanes Stephen |
Chief Medical Officer |
|
2019-09-04 |
4 |
OE |
$0.45 |
$2,700 |
D/D |
6,000 |
8,292 |
|
- |
|
Frates James M |
|
|
2019-08-15 |
4 |
AS |
$160.58 |
$1,284,640 |
D/D |
(8,000) |
2,535 |
|
- |
|
Frates James M |
|
|
2019-08-15 |
4 |
OE |
$28.35 |
$226,800 |
D/D |
8,000 |
10,535 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-07-25 |
4 |
D |
$161.38 |
$271,925 |
D/D |
(1,685) |
42,430 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
44,115 |
|
- |
|
Cloonan Michael |
Chief Business Officer |
|
2019-07-25 |
4 |
D |
$161.38 |
$175,581 |
D/D |
(1,088) |
2,102 |
|
- |
|
Cloonan Michael |
Chief Business Officer |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
3,190 |
|
- |
|
Kanes Stephen |
Chief Medical Officer |
|
2019-07-25 |
4 |
D |
$161.38 |
$88,598 |
D/D |
(549) |
2,292 |
|
- |
|
Kanes Stephen |
Chief Medical Officer |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
2,841 |
|
- |
|
Robichaud Albert |
Chief Scientific Officer |
|
2019-07-25 |
4 |
D |
$161.38 |
$88,436 |
D/D |
(548) |
95,657 |
|
- |
|
Robichaud Albert |
Chief Scientific Officer |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
96,205 |
|
- |
|
Iguchi Kimi |
CFO & Treasurer |
|
2019-07-25 |
4 |
D |
$161.38 |
$88,436 |
D/D |
(548) |
13,761 |
|
- |
|
Iguchi Kimi |
CFO & Treasurer |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
14,309 |
|
- |
|
Cook Anne Marie |
SVP, GC & Secretary |
|
2019-07-25 |
4 |
D |
$161.38 |
$136,205 |
D/D |
(844) |
1,756 |
|
- |
|
Cook Anne Marie |
SVP, GC & Secretary |
|
2019-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
2,600 |
|
- |
|
Iguchi Kimi |
CFO & Treasurer |
|
2019-07-25 |
4 |
OE |
$1.36 |
$2,720 |
D/D |
2,000 |
12,409 |
|
- |
|
Iguchi Kimi |
CFO & Treasurer |
|
2019-07-17 |
4 |
OE |
$1.36 |
$5,440 |
D/D |
4,000 |
10,409 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-07-16 |
4 |
OE |
$0.45 |
$12,150 |
D/D |
27,000 |
39,115 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-05-29 |
4 |
AS |
$169.16 |
$183,401 |
D/D |
(1,075) |
12,115 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-05-28 |
4 |
AS |
$173.62 |
$14,801,189 |
D/D |
(84,661) |
13,190 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-05-28 |
4 |
OE |
$0.45 |
$16,081 |
D/D |
35,736 |
97,851 |
|
- |
|
Jonas Jeffrey M |
President & CEO |
|
2019-05-24 |
4 |
AS |
$174.05 |
$7,065,543 |
D/D |
(40,356) |
62,115 |
|
- |
|
261 Records found
|
|
Page 4 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|